IQVIA Holdings Inc. (NYSE:IQV)

Total revenues exhibited a consistent upward trajectory between 2018 and 2022, increasing from 10,412 million US$ to 14,410 million US$. While growth was moderate between 2018 and 2020, a significant acceleration occurred in 2021, where total revenues rose by approximately 22% over the previous year.

Technology & Analytics Solutions

This segment demonstrated steady and uninterrupted growth throughout the observed period. Revenues increased from 4,137 million US$ in 2018 to 5,746 million US$ in 2022, reflecting a consistent expansion of this business line.

Research & Development Solutions

As the primary revenue driver, this segment experienced a substantial increase in 2021, rising from 5,760 million US$ in 2020 to 7,556 million US$. This surge was the chief contributor to the overall revenue spike in 2021, and the segment concluded the period as the largest contributor at 7,921 million US$ in 2022.

Contract Sales & Medical Solutions

This segment remained relatively stagnant with a slight downward trend over the five-year horizon. After peaking at 814 million US$ in 2019, revenues declined to 743 million US$ by 2022, indicating a diminishing contribution to the total revenue mix.

The revenue distribution reveals a growing concentration in Research & Development and Technology & Analytics. The contrast between the rapid growth in these sectors and the stagnation of Contract Sales & Medical Solutions suggests a shifting revenue base toward high-growth, specialized solutions.